A phase 2B randomnized, double blind, placebo controlled, multicenter, dose ranging study to evaluate the efficacy and safety profile of PF-06651600 with a partially blinded extension period to evaluate the efficacy and safety of PF-06651600 and PF-06700841 in subjects with active non segmental vitiligo.